Impaired Macrophage Efferocytosis: Shared Mechanisms and Therapeutic Implications in Immune-Mediated Inflammatory

Zelin He1, Nuoshi Chen1, Yan Zhang1

  • 1Department of Rheumatology and Immunology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, People's Republic of China.

Insights

Defective efferocytosis, the clearance of dead cells by macrophages, drives immune-mediated inflammatory diseases. Targeting this process offers a path to restoring immune balance and developing new therapies for chronic conditions.

Area of Science:

  • Immunology
  • Cell Biology
  • Pathogenesis

Background:

  • Efferocytosis is crucial for tissue homeostasis and immune tolerance, primarily mediated by macrophages.
  • Macrophages engulf apoptotic cells via specific receptors, preventing inflammation and reprogramming the immune microenvironment.
  • Defective efferocytosis is linked to numerous immune-mediated inflammatory diseases (IMIDs).

Purpose of the Study:

  • To propose defective macrophage efferocytosis as a common pathogenic mechanism in IMIDs.
  • To integrate evidence linking efferocytosis to immunometabolic and epigenetic changes in chronic inflammation.
  • To discuss therapeutic strategies targeting efferocytosis for IMIDs.

Main Methods:

  • Review of mechanistic studies on efferocytosis pathways in IMIDs.
  • Analysis of the role of TAM receptors, bridging molecules, and signaling pathways.
  • Integration of immunometabolic and epigenetic reprogramming concepts.

Main Results:

  • Dysregulation of efferocytosis pathways, including TAM receptors, contributes to IMID pathogenesis.
  • Impaired efferocytosis leads to persistent inflammation, autoantigen exposure, and tissue damage.
  • Efferocytosis dysfunction is associated with immunometabolic and epigenetic alterations.

Conclusions:

  • Defective macrophage efferocytosis is a shared pathogenic mechanism across diverse IMIDs.
  • Targeting efferocytosis pathways presents a promising strategy for restoring immune homeostasis.
  • This review provides a framework for developing precision immunomodulatory therapies for IMIDs.